Carisma Therapeutics, Inc.

NasdaqGM:CARM Stock Report

Market Cap: US$22.0m

Carisma Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Steve Kelly

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage13.2%
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenure1.7yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Dec 06
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Steve Kelly's remuneration changed compared to Carisma Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$81m

Dec 31 2023US$4mUS$461k

-US$87m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$80m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$666kUS$440k

-US$61m

Sep 30 2022n/an/a

-US$57m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$1mUS$416k

-US$41m

Compensation vs Market: Steve's total compensation ($USD3.50M) is above average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Kelly (59 yo)

1.8yrs

Tenure

US$3,504,425

Compensation

Mr. Steven Kelly, also known as Steve, is President, Chief Executive Officer and Director of Carisma Therapeutics, Inc. He served as President, Chief Executive Officer and Director of CARISMA Therapeutics...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Kelly
President1.8yrsUS$3.50mno data
Michael Klichinsky
Co-Founder & Chief Scientific Officer1.8yrsUS$1.60m1.16%
$ 255.8k
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Eric Siegel
General Counsel & Corporate Secretary1.6yrsno datano data
Tom Wilton
Chief Business Officer5yrsno datano data
Eugene Kennedy
Chief Medical Officerless than a yearno datano data
Kenneth Locke
Senior Vice President of Technical Operationsless than a yearno datano data

1.7yrs

Average Tenure

55yo

Average Age

Experienced Management: CARM's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Steven Kelly
President1.8yrsUS$3.50mno data
Saar Gill
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Sanford Zweifach
Independent Chairman of the Board1.8yrsUS$271.55k0.00099%
$ 218.3
Hyam Levitsky
Member of Scientific Advisory Boardno datano datano data
Carl June
Member of Scientific Advisory Boardno datano datano data
Nina Bhardwaj
Member of Scientific Advisory Board4.5yrsno datano data
Briggs Duncan Morrison
Independent Director1.8yrsUS$220.20k0.029%
$ 6.4k
Marella Thorell
Directorless than a yearno datano data
John Hohneker
Independent Directorless than a yearno data0%
$ 0
Lisa Coussens
Member of Scientific Advisory Boardno datano datano data
Prasad Adusumilli
Member of Scientific Advisory Board4.5yrsno datano data
Lin Guey
Member of Scientific Advisory Board1.9yrsno datano data

1.8yrs

Average Tenure

64yo

Average Age

Experienced Board: CARM's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 22:02
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carisma Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Justin ZelinBTIG
Naureen QuibriaCapital One Securities, Inc.